CA2838973A1 - Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies - Google Patents

Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies Download PDF

Info

Publication number
CA2838973A1
CA2838973A1 CA2838973A CA2838973A CA2838973A1 CA 2838973 A1 CA2838973 A1 CA 2838973A1 CA 2838973 A CA2838973 A CA 2838973A CA 2838973 A CA2838973 A CA 2838973A CA 2838973 A1 CA2838973 A1 CA 2838973A1
Authority
CA
Canada
Prior art keywords
dll4
antibody
tumor
cancer
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2838973A
Other languages
English (en)
French (fr)
Inventor
Adrian L. Harris
Stanley K. LIU
Ruth MUSCHEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2838973A1 publication Critical patent/CA2838973A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2838973A 2011-06-17 2012-06-15 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies Abandoned CA2838973A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498200P 2011-06-17 2011-06-17
US61/498,200 2011-06-17
PCT/US2012/042695 WO2012174394A1 (en) 2011-06-17 2012-06-15 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies

Publications (1)

Publication Number Publication Date
CA2838973A1 true CA2838973A1 (en) 2012-12-20

Family

ID=46397640

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2838973A Abandoned CA2838973A1 (en) 2011-06-17 2012-06-15 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies

Country Status (6)

Country Link
US (1) US8685401B2 (https=)
EP (1) EP2721070A1 (https=)
JP (1) JP2014523421A (https=)
AU (1) AU2012271450A1 (https=)
CA (1) CA2838973A1 (https=)
WO (1) WO2012174394A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
TWI821189B (zh) * 2017-06-12 2023-11-11 法商施維雅藥廠 使用組合療法治療腦腫瘤之方法
TW202440123A (zh) * 2017-06-12 2024-10-16 法商施維雅藥廠 以組合療法治療腦瘤之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
RU2581962C2 (ru) 2008-09-19 2016-04-20 Медиммун Ллк Нацеленные средства связывания, направленные на dll4, и их применение
US20110059114A1 (en) * 2009-08-05 2011-03-10 Duke University Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
US20130006034A1 (en) 2013-01-03
AU2012271450A1 (en) 2014-01-16
US8685401B2 (en) 2014-04-01
EP2721070A1 (en) 2014-04-23
WO2012174394A1 (en) 2012-12-20
JP2014523421A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
KR102628557B1 (ko) 폐암의 치료를 위한 항-pd-1 항체
US12390458B2 (en) Therapeutic combination of quinoline derivative and antibody
JP2024508894A (ja) Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
EP3347054B1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
US20230340122A1 (en) Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
US8685401B2 (en) Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies
KR20210006405A (ko) 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
CN110494161A (zh) 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
JP2025519495A (ja) がんを治療するための抗ｐｄ－１活性薬剤、抗ｔｉｍ－３活性薬剤、および抗ｌａｇ－３活性薬剤の併用療法
US20240327519A1 (en) Methods and compositions for treating cancer
CN120437288A (zh) 治疗卵巢癌的药物组合
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
WO2025103441A1 (zh) 联合抗her2抗体和化疗剂治疗胃癌的方法及用途
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
TW202430209A (zh) 單獨使用雙特異性EGFR x CD28抗體或其與抗PD-1抗體組合使用治療癌症之方法
CN112915202B (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2024041652A1 (en) Methods of cancer treatment
TW202527984A (zh) 5t4抗體藥物結合物及其使用之方法
TW202502382A (zh) 治療組合及其用途和治療方法
JP2025519552A (ja) がんの治療のためのｓｉｒｐアルファ融合タンパク質及び抗ｃｄ１９抗体を含む併用療法
TW202509063A (zh) 用抗lag3、抗pd-1和化學療法治療食管癌
HK40109234A (zh) 用於治疗癌症的方法和组合物
HK40052936B (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170615